FDA Approves New Treatment for Rare Hunter Syndrome
FDA 核准治療罕見亨特氏症的新療法
On March 25, 2026, the FDA granted accelerated approval to a new treatment called Avlayah (tividenofusp alfa-eknm) for Hunter syndrome, a rare genetic disorder.
2026年3月25日，美國食品藥物管理局（FDA）批准了一項名為Avlayah（tividenofusp alfa-eknm）的新療法，用於治療罕見遺傳疾病——亨特氏症（Hunter syndrome）。
Hunter syndrome, which mostly affects males, involves a dangerous buildup of substances in cells that leads to severe cognitive and motor decline.
亨特氏症主要影響男性，其病理特徵是細胞內有害物質堆積，進而導致嚴重的認知與運動功能衰退。
Previously available therapies could not reach the brain, but Avlayah is specifically engineered to cross the blood-brain barrier using a special delivery technology.
過去的療法無法穿透大腦，但Avlayah採用了特殊的傳輸技術，專門設計用於穿過血腦屏障（Blood-brain barrier）。
The FDA's decision to grant accelerated approval was based on a reduction of certain markers in the cerebrospinal fluid, a move that highlights the agency's willingness to use surrogate endpoints when dealing with rare diseases.
FDA授予加速批准（Accelerated approval）的決定，是基於腦脊髓液中特定標記的減少，此舉突顯了FDA在面對罕見疾病時，願意採取替代終點（Surrogate endpoints）的作法。
While this approval is a significant win for biotechnology and patient advocacy groups, it also sparks discussion about regulatory standards.
雖然這項批准對生物技術領域與病患權益倡導團體而言是一大勝利，但也引發了關於監管標準的討論。
